CeriBell (NASDAQ:CBLL) Given New $36.00 Price Target at TD Cowen

CeriBell (NASDAQ:CBLL) had its target price upped by TD Cowen from $31.00 to $36.00 in a report issued on Monday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. William Blair started coverage on CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating on the stock. Canaccord Genuity Group increased their price target on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday. JPMorgan Chase & Co. began coverage on CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target on the stock. Finally, Bank of America started coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $32.60.

CeriBell Stock Performance

CBLL stock opened at $30.04 on Monday. CeriBell has a fifty-two week low of $23.00 and a fifty-two week high of $32.53.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. As a group, research analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.